SCHEMBL37667

SCHEMBL37667

Nc1cc2ccccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 1.00
LOXL2 Q9Y4K0 1/20 0.54
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
CA2 P00918 2/20 0.50
FLT3 P36888 1/20 0.48
CYP2A6 P11509 1/20 0.48
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47
DAO P14920 2/20 0.47
HPGD P15428 2/20 0.47
SRD5A2 P31213 1/20 0.47
HSD17B10 Q99714 1/20 0.47
BRD4 O60885 1/20 0.47
DDO Q99489 1/20 0.47
GSK3B P49841 1/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
CHEK1 O14757 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29363162 1.00 AOC3 (1.00) AOC3LOXL2NPC1RAB9ACA2
Hydrochloric Acid SCHEMBL28968677 0.98 AOC3 (1.00) AOC3LOXL2NPC1RAB9ACA2
Hydrochloric Acid SCHEMBL5435898 0.98 AOC3 (1.00) AOC3LOXL2NPC1RAB9ACA2
Iodide SCHEMBL2316310 0.98 AOC3 (0.95) AOC3LOXL2NPC1RAB9ACA2
SCHEMBL28494735 0.89 AOC3 (0.80) AOC3LOXL2NPC1RAB9ACA2
Urea SCHEMBL28162531 0.89 AOC3 (0.80) AOC3LOXL2NPC1RAB9ACA2
Pyrrole SCHEMBL412879 0.89 AOC3 (0.80) AOC3LOXL2NPC1RAB9ACA2
Pyrrole SCHEMBL27718192 0.89 AOC3 (0.80) AOC3LOXL2NPC1RAB9ACA2
SCHEMBL28124326 0.88 AOC3 (0.77) AOC3LOXL2NPC1RAB9ACA2
SCHEMBL27747908 0.84 AOC3 (0.71) AOC3LOXL2NPC1RAB9ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 10759 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122095084-A Antigen-specific T cell receptors and chimeric antigen receptors and methods of use in modulation of immune signaling for cancer immunotherapy 2026-05-26 CN claimed
US-20260137817-A1 COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX GALERA LABS LLC (US) 2026-05-21 US claimed
EP-4602064-B1 METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE BACHEM HOLDING AG (CH) 2026-05-13 EP claimed
EP-4731758-A2 ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY The Methodist Hospital (US) 2026-04-29 EP claimed
EP-4688823-A2 BIFUNCTIONAL MOLECULES TARGETING LYMPH NODE PROGENITOR EXHAUSTED T CELLS AND METHODS OF USE The Board of Trustees of the Leland Stanford Junior University (US) 2026-02-11 EP claimed
EP-4076482-B1 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING CANCER PERSEPHONE BIOSCIENCES INC (US) 2025-11-26 EP claimed
US-20250304573-A1 LYSERGIC ACID DERIVATIVES AND METHODS UNIV FLORIDA STATE RES FOUND INC (US) 2025-10-02 US claimed
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
US-12415988-B2 Enhanced differentiation of mesenchymal stem cells ESCAPE THERAPEUTICS, INC. 2025-09-16 US claimed
EP-4602064-A1 METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE Bachem Holding AG (CH) 2025-08-20 EP claimed
EP-0131007-A1 GnRH AGONISTS. SALK INST FOR BIOLOGICAL STUDI (US) 1985-01-16 EP claimed
EP-0125290-A1 PEPTIDES AFFECTING GONADAL FUNCTION. SALK INST FOR BIOLOGICAL STUDI (US) 1984-11-21 EP claimed
EP-0122712-A2 GnRH antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1984-10-24 EP claimed
WO-1984002341-A1 GnRH AGONISTS SALK INST FOR BIOLOGICAL STUDI (US) 1984-06-21 WO claimed
WO-1984001771-A1 PEPTIDES AFFECTING GONADAL FUNCTION SALK INST FOR BIOLOGICAL STUDI (US) 1984-05-10 WO claimed
EP-0107963-A1 Indole derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-05-09 EP claimed
US-4342671-A FOR TREATMENT OF ACROMEGALY AND DIABETES, INHIBITS RELEASE OF GROWTH HORMONE AMERICAN HOME PRODUCTS CORPORATION (US) 1982-08-03 US claimed
EP-0004664-B1 A PROCESS FOR PREPARING LYSERGOL DERIVATIVES Corvi Mora, Enrico (IT) 1982-04-14 EP claimed
US-4232157-A Process for preparing lysergol derivatives ISTITUTO CHEMIOTERAPICO DI LODI SPA, A CORP OF ITALY (IT) 1980-11-04 US claimed
EP-0004664-A1 A process for preparing lysergol derivatives Corvi Mora, Enrico (IT) 1979-10-17 EP claimed